Molecular Cancer Therapeutics

雜志介紹

Molecular Cancer Therapeutics雜志介紹

《Molecular Cancer Therapeutics》是一本以English為主的未開放獲取國際優秀期刊，中文名稱分子癌癥治療，本刊主要出版、報道醫學-ONCOLOGY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為5.3，最新CiteScore 指數為11.2。

本刊近期中國學者發表的論文主要有：

• Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Breast Cancer

  Author: Peng, Peng; Qiang, Xiaoyan; Li, Guoyu; Li, Lin; Ni, Shumao; Yu, Qi; Sourd, Laura; Marangoni, Elisabetta; Hu, Chao; Wang, Dong; Wu, Di; Wu, Frank

• Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer

  Author: Li, Chengxun; Zhang, Jiale; Wu, Qiming; Kumar, Anuj; Pan, Guihong; Kelvin, David J.

• Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS

  Author: Wang, Xing; Raman, Natasha; Lemtiri-Chlieh, Ghali; Chang, Jinhee; Jagtap, Shreya; Chowdhury, Dipanwita Dutta; Ballew, Matthew; Carrieri, Francesca Anna; Nguyen, Triet; Nugent, Katriana; Peck, Travis; Levine, Michelle S.; Chan, Aaron; Lam, Christine; Malek, Reem; Hoang, Tung; Phillips, Ryan; Cheng, ZhuoAn; Taparra, Kekoa; Connis, Nick; Hann, Christine L.; Holland, Andrew; Tran, Phuoc T.; Lafargue, Audrey; Wang, Hailun

• Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-KB-Triggered SASP in Cancer-Associated Fibroblasts

  Author: Jin, Ping; Li, Xin; Xia, Yu; Li, Huayi; Li, Xiaoting; Yang, Zong-Yuan; Wang, Zhen; Xu, Cheng; Fang, Tian; Zhou, Dongchen; Xiong, Xiaoming; Wang, Si-Yuan; Xu, Sen; Gao, Qinglei

英文介紹

Molecular Cancer Therapeutics雜志英文介紹

Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.